Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese

Pharm Res. 1998 Apr;15(4):517-24. doi: 10.1023/a:1011913407147.

Abstract

Genetic polymorphism of drug metabolizing enzymes, particularly cytochrome P450(CYP), is an important cause of adverse drug reactions. Multiple gene mutations in CYP have been shown to be phenotype. The occurrence of genetic polymorphism has been seen in genes for CYP1A1, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A5. This review discusses the molecular mechanism of two genetic polymorphisms, debrisoquine/sparteine (CYP2D6) coumarin (CYP2A6) polymorphisms. In addition, elucidation of gene mutations of CYP2D6 and CYP2A6 in Japanese will be discussed.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aryl Hydrocarbon Hydroxylases*
  • Asian Continental Ancestry Group / genetics*
  • Base Sequence
  • Cytochrome P-450 CYP2A6
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 Enzyme System / genetics*
  • Humans
  • Japan
  • Mixed Function Oxygenases / genetics*
  • Molecular Sequence Data
  • Mutation / genetics*
  • Pharmaceutical Preparations / metabolism*
  • Phenotype
  • Polymorphism, Genetic / genetics*

Substances

  • Pharmaceutical Preparations
  • Cytochrome P-450 Enzyme System
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2A6 protein, human
  • Cytochrome P-450 CYP2A6
  • Cytochrome P-450 CYP2D6